The Company is currently focusing its development efforts on the progression of its preclinical monoclonal antibody BXL1H5 for the treatment of chronic pain, a condition that drastically impact people’s quality of life and has very high economic costs to society.

Following the conclusion of our Vitamin D3 related R&D activities in urological indications, BioXell is also looking into a number of strategic options in line with the demands of its Shareholders.

BioXell has a number of valuable assets with therapeutic and clinical potential in its pipeline. As the Company is no longer developing these assets internally for strategic reasons, BioXell is assessing out-licensing opportunities to interested partners.